Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:25:21.818Z.
Calculation as of: 2026-10-06T13:25:21.818Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca6b3f945453907090b614e1109f6f6fce8b12406cb587c45253d0481e46e17d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$32.31M
EBITDA Yield
N/A
TTM Avg
0.01%
3Y Avg
0.01%
5Y Avg
0.01%
Market Cap
$31.36M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | $33.42M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.52M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $32.32M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $32.31M | N/A | 0.01% | 0.01% | 0.01% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $35.89M | N/A | 4.27% | 2.75% | 3.74% |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $36.05M | N/A | 15.63% | 9.19% | 7.93% |
| CervoMed Inc. (CRVO)vs › | $30.65M | N/A | 392.49% | 233.09% | 233.09% |
| HeartBeam, Inc. (BEAT)vs › | $36.31M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
